Hyperlipidemia NCEP recommendations for drug therapy of high-risk hyperlipidemia in children and adolescents: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
(/* Original Recommendations of the National Cholesterol Education Program (NCEP) Expert Panel for Drug Therapy of High-Risk Hyperlipidemia in Children and Adolescents {{cite journal| author=McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinb...) |
||
Line 11: | Line 11: | ||
{{cquote| | {{cquote| | ||
* Consider drug therapy in children | * Consider drug therapy in children ≥ 10 years of age (usually wait until [[menarche]] for females) and after a 6- to 12-month trial of fat- and cholesterol-restricted dietary management. | ||
* Consider drug therapy if | * Consider drug therapy if | ||
** [[LDL]] level remains | ** [[LDL]] level remains ≥ 4.90 mmol/L (190 mg/dL) or | ||
** [[LDL]] remains >4.10 mmol/L (160 mg/dL) and there is a positive family history of premature cardiovascular disease or | ** [[LDL]] remains > 4.10 mmol/L (160 mg/dL) and there is a positive family history of premature cardiovascular disease or ≥ 2 other risk factors are present in the child or adolescent after vigorous attempts to control these risk factors. | ||
* Referral to specialized lipid center may be deemed appropriate. | * Referral to specialized lipid center may be deemed appropriate. | ||
* Treatment goal | * Treatment goal | ||
** Minimal, LDL <3.35 mmol/L (130 mg/dL) | ** Minimal, LDL < 3.35 mmol/L (130 mg/dL) | ||
** Ideal, LDL <2.85 mmol/L (110 mg/dL) | ** Ideal, LDL < 2.85 mmol/L (110 mg/dL) | ||
}} | }} | ||
Latest revision as of 18:56, 19 February 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Lipoprotein Disorders Microchapters |
Overview
Children and adolescents with high-risk hyperlipidemia require lipid-lowering drug therapy, particularly those with familial hypercholesterolemia, despite compliance with lifestyle recommendations.
NCEP Recommendations for Drug Therapy of High-Risk Hyperlipidemia in Children and Adolescents
Original Recommendations of the National Cholesterol Education Program (NCEP) Expert Panel for Drug Therapy of High-Risk Hyperlipidemia in Children and Adolescents [1] (DO NOT EDIT)
“ |
|
” |
Current Modifications of the National Cholesterol Education Program (NCEP) Expert Panel for Drug Therapy of High-Risk Hyperlipidemia in Children and Adolescents [1] (DO NOT EDIT)
“ |
|
” |
References
- ↑ 1.0 1.1 McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP; et al. (2007). "Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing". Circulation. 115 (14): 1948–67. doi:10.1161/CIRCULATIONAHA.107.181946. PMID 17377073.